-
70290-5000(S)-Naproxen is a non-selective COX inhibitor. The IC<sub>50</sub> values for human recombinant COX-1 and -2 are 0.6-4.8 µM and 2.0-28.4 µM, respectively.
-
13891-1An analog of (&minus)-blebbistatin that is stable to prolonged irradiation at 450-490 nm and has been successfully used in fluorescent live cell imaging.
-
13891-10An analog of (&minus)-blebbistatin that is stable to prolonged irradiation at 450-490 nm and has been successfully used in fluorescent live cell imaging.
-
13891-25An analog of (&minus)-blebbistatin that is stable to prolonged irradiation at 450-490 nm and has been successfully used in fluorescent live cell imaging.
-
13891-5An analog of (&minus)-blebbistatin that is stable to prolonged irradiation at 450-490 nm and has been successfully used in fluorescent live cell imaging.
-
19696-1A methylsulfanylimidazole that inhibits p38 MAP kinase (IC<sub>50</sub> = 0.90 µM in vitro) potently blocks the release of TNF-&alpha and IL-1&beta from human peripheral blood mononuclear cells (IC<sub>50</sub>s = 0.
-
19696-10A methylsulfanylimidazole that inhibits p38 MAP kinase (IC<sub>50</sub> = 0.90 µM in vitro) potently blocks the release of TNF-&alpha and IL-1&beta from human peripheral blood mononuclear cells (IC<sub>50</sub>s = 0.
-
19696-5A methylsulfanylimidazole that inhibits p38 MAP kinase (IC<sub>50</sub> = 0.90 µM in vitro) potently blocks the release of TNF-&alpha and IL-1&beta from human peripheral blood mononuclear cells (IC<sub>50</sub>s = 0.
-
19696-500A methylsulfanylimidazole that inhibits p38 MAP kinase (IC<sub>50</sub> = 0.90 µM in vitro) potently blocks the release of TNF-&alpha and IL-1&beta from human peripheral blood mononuclear cells (IC<sub>50</sub>s = 0.
-
18119-1The inactive enantiomer of the SET7/9 inhibitor (R)-PFI-2 that may serve as a negative control.
-
18119-10The inactive enantiomer of the SET7/9 inhibitor (R)-PFI-2 that may serve as a negative control.
-
18119-5The inactive enantiomer of the SET7/9 inhibitor (R)-PFI-2 that may serve as a negative control.